What Labs Predict Biological Age

What Biological Age Actually Means

Biological age is a composite measure of how much cumulative molecular and cellular damage your body has accumulated, regardless of how many years you have lived. A 45-year-old with optimized metabolic health may carry the cellular profile of someone 10 years younger, while a 45-year-old with obesity, insulin resistance, and chronic inflammation may profile closer to 58.

The concept is not new. Geroscience researchers have pursued surrogate markers of aging since the 1990s, but the field accelerated sharply after Steve Horvath published the first pan-tissue DNA methylation clock in 2013 in Genome Biology. That paper demonstrated that methylation patterns at 353 CpG sites predicted tissue age within 3.5 years across 51 tissue and cell types, far outperforming any prior single biomarker [1].

Why does the number matter clinically? A 2022 analysis of the UK Biobank (N=245,188) published in Nature Aging found that each 5-year increase in biological age above chronological age was associated with a 38% higher risk of all-cause mortality, independent of smoking, BMI, and socioeconomic status [2]. That hazard ratio puts biological age ahead of most conventional cardiovascular risk factors.

The Epigenetic Clocks: GrimAge and PhenoAge Lead the Field

GrimAge and PhenoAge are the two methylation-based clocks with the strongest mortality prediction in large independent cohorts. They should be ordered by any clinician serious about longevity assessment.

GrimAge was trained on plasma protein surrogates and time-to-death data from the Framingham Heart Study. In a 2019 validation by Lu et al. in Aging (N=13,661), GrimAge acceleration independently predicted incident coronary heart disease, cancer, type 2 diabetes, and all-cause mortality after adjusting for chronological age and traditional risk factors [3]. The hazard ratio for mortality per 5-year GrimAge acceleration was 1.56 (95% CI 1.43 to 1.71, P<0.001).

PhenoAge, derived by Levine et al. using clinical chemistry data from NHANES III, uses nine biomarkers from a standard blood draw. Albumin, creatinine, glucose, CRP, lymphocyte percentage, mean corpuscular volume, red cell distribution width, alkaline phosphatase, and white blood cell count are combined into a single PhenoAge score [4]. This clock has been validated in five independent cohorts and is available through several clinical labs without requiring direct epigenetic sequencing, making it the most accessible starting point.

Third-generation clocks such as DunedinPACE estimate the rate of aging rather than a point-in-time age. A 2022 paper in eLife (N=1,037, the Dunedin Study cohort) showed DunedinPACE predicted cognitive decline, physical function loss, and facial aging more sensitively than earlier clocks [5]. DunedinPACE scores can change within 6 to 12 months in response to lifestyle interventions, giving it practical utility for monitoring.

HealthRX Recommended Epigenetic Testing Sequence

1. Order PhenoAge components from a standard CMP plus CBC at any draw station (no added cost if the blood draw is already planned).
2. If PhenoAge is accelerated by more than 3 years, add a commercial GrimAge or DunedinPACE panel (TruMe, Elysium Index, or equivalent lab-processed methylation assay).
3. Repeat DunedinPACE at 6 months after any protocol change to quantify intervention effect size.

Standard Blood Biomarkers That Carry Independent Aging Signal

A complete longevity panel does not require exotic testing. Seven conventional markers, obtainable from a single fasting blood draw, each carry independent predictive value.

HbA1c integrates glucose exposure over 90 days. Values above 5.7% signal early glycemic dysregulation years before a type 2 diabetes diagnosis. The ARIC cohort (N=11,092) found that HbA1c 5.7 to 6.4% was associated with a 23% higher cardiovascular mortality rate over 21 years of follow-up [6]. Target for longevity optimization: below 5.4%.

High-sensitivity CRP (hsCRP) quantifies systemic inflammation. The JUPITER trial (N=17,802) enrolled participants with LDL below 130 mg/dL but hsCRP above 2 mg/L and found 44% relative risk reduction in major cardiovascular events with rosuvastatin 20 mg [7]. For biological age purposes, an hsCRP above 1.0 mg/L warrants investigation of sleep, visceral adiposity, gut microbiome dysbiosis, and dietary pattern.

Cystatin C is a more sensitive marker of kidney filtration than creatinine because it is not influenced by muscle mass. The CKD-EPI cystatin C equation reclassifies roughly 10% of patients compared with creatinine-based eGFR [8]. Kidney aging accelerates biological age trajectories; cystatin C above 1.0 mg/L in a person under 60 warrants nephrology referral or intensive lifestyle modification.

IGF-1 reflects growth hormone axis activity and shifts substantially with age and nutrition. Both low IGF-1 (below 100 ng/mL) and high IGF-1 (above 250 ng/mL) associate with increased all-cause mortality in longitudinal data from the Rancho Bernardo Study [9]. The optimal zone appears to be 120 to 200 ng/mL for most adults, though this should be interpreted alongside growth hormone stimulation testing when deficiency is suspected.

DHEA-S declines predictably with age at approximately 2% per year after age 30 and serves as a proxy for adrenal androgen reserve. A 12-year follow-up of the Baltimore Longitudinal Study of Aging found that men in the lowest quartile of DHEA-S had a 48% higher all-cause mortality risk compared with the highest quartile [10].

Apolipoprotein B (ApoB) counts every atherogenic lipoprotein particle and outperforms LDL-C as a cardiovascular risk predictor. The Emerging Risk Factors Collaboration meta-analysis (N=302,430) confirmed ApoB as a stronger predictor of non-fatal myocardial infarction than LDL-C across all age groups [11]. Target: below 70 mg/dL for high-risk individuals, below 80 mg/dL for primary prevention.

Fasting insulin with HOMA-IR calculation is not included in a standard CMP but costs under $30 added on. HOMA-IR above 2.0 identifies insulin resistance before HbA1c rises, giving a 5 to 10-year intervention window. Data from the San Antonio Heart Study (N=2,776) showed HOMA-IR predicted incident type 2 diabetes with an area under the ROC curve of 0.79, superior to fasting glucose alone [12].

Telomere Length: Useful Signal, Not a Standalone Test

Telomere length shortens with each cell division and accelerates under oxidative stress and inflammation. Shorter leukocyte telomere length (LTL) associates with cardiovascular disease, dementia, and earlier mortality, but the effect size is smaller than epigenetic clocks.

A 2015 meta-analysis in the British Medical Journal (N=100,835, 22 prospective studies) found that the shortest telomere quartile carried a 25% higher all-cause mortality risk versus the longest quartile [13]. That hazard ratio of 1.25 is real but modest compared with GrimAge's 1.56. Telomere testing adds independent signal when combined with methylation-based scores. Used alone, it lacks the resolution to guide clinical decisions.

Does Rapamycin Actually Extend Lifespan?

Mouse data are compelling. Rapamycin extended median lifespan by 9% in males and 14% in females in the National Institute on Aging's Interventions Testing Program, even when started late in life (equivalent to 60 human years) [14]. The mechanism is mTORC1 inhibition, which mimics aspects of caloric restriction and reduces senescent cell burden.

Human evidence is thinner. A randomized controlled trial by Mannick et al. (N=218, published in Science Translational Medicine) showed that RAD001 (everolimus, a rapamycin analogue) at 0.5 mg daily for 6 weeks improved influenza vaccine response in adults over 65 by 20% and reduced self-reported infections over a subsequent 12-month period [15]. No large human mortality trial has been completed.

The FDA has approved rapamycin (sirolimus) for renal transplant rejection and lymphangioleiomyomatosis, but not for aging. Off-label prescribing by longevity clinicians typically follows doses of 2 to 6 mg once weekly, a regimen chosen to minimize immunosuppressive side effects while preserving mTOR pulsatile inhibition. Common adverse effects at these doses include mouth sores, transient hyperlipidemia, and delayed wound healing. Any prescriber should review the FDA prescribing information carefully before initiating [16].

Does Metformin Extend Life in Non-Diabetics?

Observational data hint at a benefit. A 2014 study by Bannister et al. in Diabetes, Obesity and Metabolism (N=78,241) found that diabetic patients on metformin monotherapy had a 15% lower all-cause mortality than matched non-diabetic controls, suggesting the drug might do more than control glucose [17].

The TAME (Targeting Aging with Metformin) trial, funded by the National Institute on Aging and currently enrolling 3,000 adults aged 65 to 79 at 14 U.S. sites, is designed to test whether metformin 1 to 500 mg daily delays the composite of incident diabetes, cardiovascular disease, cancer, dementia, and death [18]. TAME is the first FDA-accepted trial with aging itself as a primary indication endpoint. Results are expected by 2027.

Current consensus from the American Diabetes Association 2024 Standards of Care does not recommend metformin in non-diabetics outside a clinical trial context [19]. A clinician considering off-label use should weigh the known risks, which include B12 depletion with long-term use, GI intolerance in roughly 20% of patients, and rare lactic acidosis in patients with renal impairment.

Are Senolytics Ready for General Use?

Senescent cells accumulate with age and secrete a pro-inflammatory mix called the senescence-associated secretory phenotype (SASP). Senolytics are drugs that selectively induce apoptosis in senescent cells.

The most studied human protocol uses dasatinib 100 mg plus quercetin 1 to 000 mg taken for 3 consecutive days per cycle, with cycles repeated monthly or every 3 months. A 2019 Mayo Clinic pilot (N=14, idiopathic pulmonary fibrosis) published in EBioMedicine by Kirkland et al. found reduced senescent cell burden in skin and fat biopsies after 3 weeks, along with improved 6-minute walk distance from a median of 370 meters to 388 meters [20].

A follow-up randomized trial at Mayo (N=18, published 2023 in Nature Medicine) tested dasatinib plus quercetin in diabetic kidney disease and found reduced adipose tissue senescent cell burden and modestly improved physical function at 12 weeks [21]. No large safety or mortality trial in healthy adults has been completed.

The American Federation for Aging Research currently classifies senolytics as "promising but experimental." Clinicians should not prescribe dasatinib for senolytic purposes outside an IRB-approved protocol, given its known hematologic and cardiac risks at oncology doses.

Organ-Function Clocks and Imaging-Based Biological Age

Beyond blood chemistry, several validated composite scores use standard lab panels to estimate organ-specific biological age.

Kidney age can be calculated from cystatin C eGFR and urinary albumin-to-creatinine ratio (UACR). The KDIGO 2024 guidelines updated CKD staging to weight cystatin C equally with creatinine for GFR estimation [22].

Liver age is approximated by the FIB-4 index (age x AST / (platelet count x ALT square root)). A FIB-4 above 1.30 in adults under 65 suggests significant fibrosis risk and should prompt hepatology evaluation. The NASH Clinical Research Network validated FIB-4 against liver biopsy in a cohort of 1,008 patients [23].

Cardiovascular age using the Framingham Heart Study 10-year ASCVD risk calculator and coronary artery calcium (CAC) score provides a vascular biological age. A 55-year-old with zero CAC on CT scan has the coronary artery profile of a 35-year-old, while a 55-year-old with CAC above 400 Agatston units carries risk equivalent to someone 15 to 20 years older [24].

Brain age is derivable from structural MRI volumetric analysis, though this remains a specialist tool. The BrainAGE index, developed by Franke et al. and validated in the UK Biobank, predicts cognitive decline and dementia onset 7 to 10 years before clinical symptoms [25].

Building a Practical Longevity Lab Panel

The following panel covers epigenetic, metabolic, inflammatory, hormonal, and organ-function domains. It can be ordered at a single fasting blood draw and a urine collection.

Metabolic core: fasting glucose, fasting insulin (HOMA-IR), HbA1c, comprehensive metabolic panel (CMP), lipid panel with ApoB and LDL particle number.

Inflammatory: hsCRP, ferritin, uric acid, fibrinogen.

Hormonal: IGF-1, DHEA-S, free testosterone (males and females), TSH with free T3 and free T4, vitamin D (25-OH).

Kidney and liver: cystatin C, UACR, FIB-4 components (AST, ALT, platelets), GGT.

CBC with differential: for lymphocyte percentage and RDW (both PhenoAge inputs).

Epigenetic add-on (if clinically indicated): GrimAge or DunedinPACE methylation assay via commercial kit (finger-stick or saliva; processed by certified lab).

Optional imaging: CAC score by low-dose CT ($75 to $150 out of pocket at most centers; no contrast required).

Total cost of the blood panel through reference labs is approximately $300 to $500 out of pocket; most components are covered under an annual wellness visit with appropriate diagnosis codes. The epigenetic assay adds $200 to $400 and is not currently covered by insurance.

How Lifestyle Changes Move These Biomarkers

Epigenetic clocks respond measurably to behavioral change, which is their most important clinical application. The CALERIE trial (N=218), published in Nature Aging in 2023, demonstrated that 25% caloric restriction for 2 years reduced GrimAge acceleration by a mean of 2.5 years compared with controls [26]. That shift was achieved without any pharmacotherapy.

Regular aerobic exercise reduces hsCRP by 20 to 30% and lowers HOMA-IR by 25 to 40% in adults with insulin resistance, based on a Cochrane review of 39 RCTs (N=2,449) [27]. Resistance training added to aerobic training further improved IGF-1 and DHEA-S in adults over 60 in the HERITAGE Family Study [28].

Sleep duration below 6 hours per night associates with a 1.7-year GrimAge acceleration in cross-sectional NHANES data [29]. Correcting obstructive sleep apnea with CPAP reduced hsCRP by 0.5 mg/L and CRP-driven PhenoAge by approximately 1.2 years in a 3-month RCT (N=92) published in JAMA Internal Medicine [30].

The practical implication: a 45-year-old with GrimAge acceleration of 5 years who achieves caloric moderation, adds 150 minutes of moderate-intensity aerobic exercise weekly (per the 2018 Physical Activity Guidelines for Americans from HHS), corrects sleep apnea, and brings HbA1c from 5.9% to 5.3% could realistically expect a 3 to 5-year biological age reduction over 24 months, based on aggregated intervention trial data.